Forecyte Bio, a leading China-based CDMO biotech company, recently celebrated the grand opening of its new facility in Frederick County, Maryland. The 17,000 square foot location is dedicated to contract development and manufacturing for the rapidly growing Cell and Gene Therapy industry. The facility aims to provide a “one-stop” holistic service package to help accelerate clients’ projects from early concept to commercial manufacturing.
In the hustle and bustle of planning experiments, growing a business and improving services, visual branding often stumbles toward the bottom of the priorities list for life science companies. While companies used to be able to get away with quickly putting a logo together and creating a scrappy website using a pre-existing Wix template, an increasingly crowded life sciences market is making leadership teams rethink their visual presence.
The JP Morgan Healthcare conference (JPM23) is running January 9-13, 2023, in San Francisco. It’s one of the biggest biotech conferences, possibly the biggest, with companies from all over the world coming (or attending virtually) to network with possible investors, present their companies’ progress and breakthrough, announce their annual financial and milestone guidance, and negotiate deals.
Baltimore, MD is continuing to emerge as one of the next great cities for medtech and medical device innovation. That’s just one of the reasons that Maryland was selected to host MedTech Innovator (MTI) and BioTools Innovator (BTI) for their East Coast pitch events on March 28-31, 2023. MTI and BTI are the largest and highest-performing global pitch competitions and accelerator programs for the life sciences field. Companies can apply before January 31st.
Bio-Trac and ATCC, the world’s premier biological materials management and standards organization, have partnered to conduct a “Best Practices in Mammalian Cell Culture” training workshop to offer a comprehensive overview of the principles and techniques related to cell culture techniques.
Rockville, Maryland’s American Gene Technologies (AGT™) HIV cure program has been making remarkable progress in its mission to bring a single-dose cure to people living with HIV. That mission is steadily advancing through a successful Phase 1 human clinical trial. The company hopes to begin its Phase 2 study during 2023; this could yield very compelling data towards a functional cure, occurring perhaps as early as the first half of 2024.
As Maryland continues to blossom as a medtech powerhouse, TEDCO has played an instrumental role in providing capital, resources and mentorship. This was especially true in q4 2022, where TEDCO invested over $1 million combined into LASARRUS, Linshom Medical, NanoBioFAB, CoolTech and Mi-Helper.
In Prince William County, 2023 is kicking off with a new round of IGNITE Startup Grants that will provide funding for high-growth entrepreneurs who want to call the area home.
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc., a biotechnology company developing novel, off the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors.
Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment
Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase 2a clinical trial of AB-101a, a topical therapeutic for mild-to-moderate atopic dermatitis (AD). The trial met all of its primary endpoints, highlighting AB-101a’s potential to be an effective and safe treatment for AD.